"Growing Biodefense Focus and Vaccine Innovation"
- A key trend shaping the Tularemia market is increasing governmental and institutional focus on biodefense. Research funding for tularemia vaccines and biologic countermeasures is rising, especially in the U.S. and Europe.
- For instance, in March 2024, the U.S. NIH funded Phase I trials for a live attenuated tularemia vaccine candidate. Similarly, the EU Horizon project in late 2023 allocated grants to develop diagnostics and vaccine pipelines targeting bioterror pathogens like F. tularensis.
